Analisis Karakteristik Pasien terhadap Tingkat Polifarmasi Peserta Prolanis di Puskesmas Dewantara Aceh Utara
Abstract
Kata kunci: Prolanis, polifarmasi, penyakit kronis, jumlah diagnosis, usia, pelayanan kesehatan primer.
Full Text:
PDFReferences
Ngowi J, Munishi C, Ndumwa H, et al. Efforts to address the burden of non-communicable diseases need local evidence and shared lessons from high-burden countries. Ann Glob Health. 2023;89(1):87. doi:10.5334/aogh.4265.
Vitorino LM, Mendes JHL, Santos GS, et al. Prevalence of polypharmacy of older people in a large Brazilian urban center and its associated factors. Int J Environ Res Public Health. 2023;20(10):5903. doi:10.3390/ijerph20105903.
Nasab NF, Rezaeian S, Ezadi S, et al. Prevalence and determinants of polypharmacy: a cross-sectional study among elderly patients with cardiovascular diseases in outpatient clinics. Scientifica (Cairo). 2025;2025 ID. doi:10.1155/2025/xxxxxxxx.
Febriyanti RM, Irawan AA, Anggriani N, et al. Challenges in implementing Indonesia's community-based chronic disease management program (Prolanis): a scoping review. AIMS Public Health. 2025;12(3):1744-1763. doi:10.3934/publichealth.2025093.
Lisni I, Lestari K, Andalusia LR. Polypharmacy in type 2 diabetes patients of the PROLANIS program in Indonesia: identification of potential drug-drug interaction. Jordan J Pharm Sci. 2025. doi:10.35516/jjps.v18i1.1818.
Delara M, Murray L, Jafari B, et al. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr. 2022;22:601. doi:10.1186/s12877-022-03279-x.
Molino CGRC, Chocano-Bedoya P, Sadlon A, et al. Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH. BMJ Open. 2022;12. doi:10.1136/bmjopen-2021-051881.
Jerjes W, Majeed A. Polypharmacy as a chronic condition: a diagnostic mindset for safer and smarter care. J Clin Med. 2025;14. doi:10.3390/jcmxxxxxxxx.
Purnamasari D. The emergence of non-communicable disease in Indonesia. Acta Med Indones. 2018;50(4):273-274.
Yuliarni I, Komara E, Handayani N. Evaluasi manajemen Program Pengelolaan Penyakit Kronis (Prolanis) dalam meningkatkan kualitas pelayanan BPJS Kesehatan di Puskesmas Singgani Kota Palu. ManBiz J Manag Bus. 2025;4(1):1-12.
Rachmawati S, Prihhastuti-Puspitasari H, Zairina E. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review. J Basic Clin Physiol Pharmacol. 2019;30(6). doi:10.1515/jbcpp-2019-0355.
Matthias A, Fernando G, Somathilake BGK, et al. Predictors and patterns of polypharmacy in chronic diseases in a middle-income country. Int J Physiol Pathophysiol Pharmacol. 2021;13(6):234-242.
Johansson KS, Jimenez-Solem E, Petersen T, et al. Increasing medication use and polypharmacy in type 2 diabetes: the Danish experience from 2000 to 2020. Diabetes Care. 2024;47(7):1184-1192. doi:10
Alkaff F, Illavi F, Salamah S, et al. The impact of the Indonesian Chronic Disease Management Program (PROLANIS) on metabolic control and renal function of type 2 diabetes mellitus patients in primary care setting. J Prim Care Community Health. 2021;12:2150132720984409. doi:10.1177/2150132720984409.
Aubert CE, Streit S, da Costa BR, et al. Polypharmacy and specific comorbidities in university primary care settings. Eur J Intern Med. 2016;35:35-42. doi:10.1016/j.ejim.2016.05.022.
Wang J, Feng Z, Dong Z, et al. Does having a usual primary care provider reduce polypharmacy behaviors of patients with chronic disease? A retrospective study in Hubei Province, China. Front Pharmacol. 2022;12:794863. doi:10.3389/fphar.2021.794863.
Kim S, Lee H, Park J, et al. Global and regional prevalence of polypharmacy and related factors, 1997–2022: an umbrella review. Arch Gerontol Geriatr. 2024;121:105394. doi:10.1016/j.archger.2024.105394.
DOI: https://doi.org/10.30743/best.v9i2.14200
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution 4.0 International License.


1.jpg)














